Population-Based Case-Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk
Top Cited Papers
Open Access
- 21 December 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 102 (3), 179-186
- https://doi.org/10.1093/jnci/djp467
Abstract
Consumption of Chinese herbs that contain aristolochic acid (eg, Mu Tong) has been associated with an increased risk of urinary tract cancer. We conducted a population-based case–control study in Taiwan to examine the association between prescribed Chinese herbal products that contain aristolochic acid and urinary tract cancer. All patients newly diagnosed with urinary tract cancer (case subjects) from January 1, 2001, to December 31, 2002, and a random sample of the entire insured population from January 1, 1997, to December 31, 2002 (control subjects), were selected from the National Health Insurance reimbursement database. Subjects who were ever prescribed more than 500 pills of nonsteroidal anti-inflammatory drugs and/or acetaminophen were excluded, leaving 4594 case patients and 174 701 control subjects in the final analysis. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multivariable logistic regression models for the association between prescribed Chinese herbs containing aristolochic acid and the occurrence of urinary tract cancer. Models were adjusted for age, sex, residence in a township where black foot disease was endemic (an indicator of chronic arsenic exposure from drinking water [a risk factor for urinary tract cancer]), and history of chronic urinary tract infection. Statistical tests were two-sided. Having been prescribed more than 60 g of Mu Tong and an estimated consumption of more than 150 mg of aristolochic acid were independently associated with an increased risk for urinary tract cancer in multivariable analyses (Mu Tong: at 61–100 g, OR = 1.6, 95% CI = 1.3 to 2.1, and at >200 g, OR = 2.1, 95% CI = 1.3 to 3.4; aristolochic acid: at 151–250 mg, OR = 1.4, 95% CI = 1.1 to 1.8, and at >500 mg, OR = 2.0, 95% CI = 1.4 to 2.9). A statistically significant linear dose–response relationship was observed between the prescribed dose of Mu Tong or the estimated cumulative dose of aristolochic acid and the risk of urinary tract cancer ( P < .001 for both). Consumption of aristolochic acid–containing Chinese herbal products is associated with an increased risk of cancer of the urinary tract in a dose-dependent manner that is independent of arsenic exposure.Keywords
This publication has 28 references indexed in Scilit:
- Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acidNephrology, 2009
- Urinary tract infections and reduced risk of bladder cancer in Los AngelesBritish Journal of Cancer, 2009
- Aristolochic acid nephropathy: A worldwide problemKidney International, 2008
- The prescribing of Chinese herbal products in Taiwan: a cross‐sectional analysis of the national health insurance reimbursement databasePharmacoepidemiology and Drug Safety, 2008
- Late Onset of Bladder Urothelial Carcinoma After Kidney Transplantation for End-Stage Aristolochic Acid Nephropathy: A Case Series With 15-Year Follow-upAmerican Journal of Kidney Diseases, 2008
- Aristolochic Acid and ???Chinese Herbs Nephropathy???Drug Safety, 2003
- Cancer and HerbsThe New England Journal of Medicine, 2000
- Urothelial Carcinoma Associated with the Use of a Chinese Herb (Aristolochia fangchi)The New England Journal of Medicine, 2000
- Epidemiology and etiology of bladder cancerSeminars in Surgical Oncology, 1997
- Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbsThe Lancet, 1993